Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 144   

Articles published

NVS 94.61 +0.04 (0.04%)
price chart
GSK Shareholders In Favor Of Novartis (NVS) Deal
GlaxoSmithKline plc (ADR) (NYSE:GSK) announced that its shareholders voted in ´┐Żoverwhelming majority´┐Ż in favor of the company's multi-billion swapping deal with Novartis AG (ADR) (NYSE:NVS) in the annual shareholder meeting held on December 18.
Related articles »  
Novartis AG ADR (NVS): New Analyst Report from Zacks Equity Research ...
Novartis reported third-quarter 2014 earnings per share of $1.33, up 48% from the year-ago period. Core earnings per share came in at $1.37, up 10% from the year-ago period and beat the Zacks Consensus Estimate of $1.29.
Related articles »  
FDA Okays Novartis AG's (NVS) Signifor LAR To Treat Acromegaly
Novartis AG (ADR) (NYSE:NVS) announced Tuesday that its drug Signifor LAR has been approved by the US Food and Drug Administration (FDA) to treat acromegaly in patients on whom prior treatments have not worked or for whom surgery is not an option.
Related articles »  
Novartis (NVS) Beats Johnson & Johnson (JNJ) In Clinical Trial
Novartis AG's (ADR) (NYSE:NVS) plaque psoriasis treatment Cosentyx continued to produce impressive results in its clinical trial.
Related articles »  
Novartis AG (ADR) (NVS) Beats Analyst Estimates; Is Expected To Perform Well ...
On the deal between Novartis AG (ADR) (NYSE:NVS) and Google Inc. (NASDAQ:GOOGL), Rundquist said that the deal is interesting for both the companies and the deal represents a new way to thinking in healthcare, by combining bio-technology healthcare ...
Related articles »  
Here's Why Novartis AG (NVS) Stock Could Fall Today
Novartis AG (ADR) (NYSE:NVS) announced early Monday morning that its drug Gilenya failed to meet its primary endpoint in a Phase III study, called INFORMS, designed to measure the efficacy of the drug in treating primary-progressive multiple sclerosis ...
Related articles »  
Stocks Alert: Novartis AG (ADR) (NYSE:NVS), Chimerix Inc (NASDAQ:CMRX ...
Novartis AG (ADR) (NYSE:NVS) said three members of its executive committee will leave the health-care company following the completion of the sales of its animal health, OTC drugs, and vaccine units to Eli Lilly (LLY) and GlaxoSmithKline (GSK).
Related articles »  
Novartis (NVS) Fails To Sidestep Patent Infringement
Novartis AG (ADR) (NYSE:NVS) has failed to invalidate Amgen Inc.'s (NASDAQ:AMGN) patents for the autoimmune drug Enbrel, as the US patent court decided to dismiss the suit filed by the former's generic division, Sandoz Inc. The company sought a ruling ...
Related articles »  
Investor Watch: Novartis AG (ADR) (NYSE:NVS), Whiting Petroleum Corp (NYSE ...
Novartis AG (ADR) (NYSE:NVS) was upgraded to a equal weight rating by analysts at Morgan Stanley. Analysts at Morgan Stanley believe that the company provides prime value to investors going forward and the growth trajectory for the company looks intact ...
Novartis AG Rating Increased to Equal Weight at Morgan Stanley (NVS)  Mideast Time
Related articles »  
Novartis AG (ADR) Boosts its Cancer Immunotherapy Presence
Despite outstanding performance over the past year from biotech and pharma, you wouldn't be alone if you think they have more room to grow.
Novartis (NVS) to acquire start-up CoStim Pharmaceuticals in immunotherapy ...  Stockhouse
Related articles »